Perlstein Lab

Leave no mutation behind

PLab is the first Public Benefit Corporation accelerating precision drug discovery for 5,000+ rare genetic diseases.

Browse our press

  • 1 in 12 people has an orphan disease. 95% of orphan diseases have no treatment.

  • Each disease is caused
    by a spectrum of genetic mutations.

  • Perlstein Lab studies each mutation
    in model organisms to produce precision medicine.

Blog

From primary screen to mouse validation, Part Two

Five months ago we introduced PERL101, one of our lead compounds for Niemann-Pick Type C (NPC) disease, in Part One. Here in Part Two we pick up the thread. On this journey we’ve progressed from nematodes to patient cells to mice with an unoptimized primary screening hit, bypassing hit-to-lead and shortening lead optimization. As we begin breeding up […]